Pralatrexate is the first and only drug approved by the US FDA to be used as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), which comprises a biologically diverse group of aggressive blood cancers. This drug represents a new treatment option for patients with relapsed or refractory PTCL.
Having no alternatives for this drug, the originator (FOLOTYN) will cost even up to 30,000 USD/month which is not affordable for a huge range of patients.
Hence, we have developed this product, with the tradename of “FOLYPRA”, at an absolutely affordable price in order to be available for patients all around the world.
In order to meet our commitments and accomplish our missions, we managed to provide “FOLYPRA” for the patients in Turkey for the first time and this product would be available in more than 6 other countries very soon.
As a reminder for World Blood Cancer Day which is dedicated for global awareness, we would like to show our sincere supports to anyone suffering from all types of cancers and we hope to see a more luminous tomorrow for all of the patients.
#zima #export #theworldinyourhands #oncology #orphandrugs #unlicensed #medicines
